View Cart  

EC Cracks Down on ‘Pay-for-Delay,’ Charging Slew of Generic Makers

The European Commission (EC) has accused two brand drugmakers of violating antitrust rules by engaging in “pay-for-delay” agreements with a slew of generic companies, sending both the brand and generic companies Statement of Objections notices.

To View This Article:


Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00